GlaxoSmithKline (GSK) is investigating a sale of its drinks businesses, Lucozade and Ribena. “In line with this strategic focus, we have decided to initiate a review evaluating all strategic options for the Lucozade and Ribena drinks brands, which are primarily marketed in established western markets. These brands are iconic and the review will look at the best ways to ensure their continued growth,” Sir Andrew Witty, Chief Executive Officer reported in its results announcement.
